Yervoy for advanced melanoma - Details


( Last Updated : May 18, 2012)
Generic Name:
Ipilimumab
Project Status:
Complete
Therapeutic Area:
Advanced Melanoma
Manufacturer:
Bristol-Myers Squibb Canada
Brand Name:
Yervoy
Project Line:
Reimbursement Review
Project Number:
PC0003-000
NOC Date:

Details


Strength:
5 mg/mL
Tumour Type:
Skin and Melanoma
Indications:
Advanced Melanoma
Funding Request:
Treatment of advanced melanoma (unresectable Stage III and IV melanoma) in patients who have received prior systemic therapy
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Bristol-Myers Squibb Canada
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request:
Treatment of advanced melanoma (unresectable Stage III and IV melanoma) in patients who have received prior systemic therapy
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.